Abstract: Objective To observe the clinical efficacy of entecavir combined with Bailing capsule in the treatment of patients with chronic hepatitis B. Methods 254 patients with CHB were randomly divided into group A and group B （n=127）. Patients in group A was treated with entecavir,and patients in group B was treated with entecavir combined with Bailing capsule. Results At the end of 24 w and 48 w treatment,serum HBsAg levels in group B were （3.2±0.3） lg IU/mL and （3.3±0.4） lg IU/mL,significantly lower than in group A （3.7±0.4）lg IU/mL and （3.6±0.5）lg IU/mL （P<0.05）;serum HBeAg levels were （1.6±0.2） lg PEIU /mL and （1.4±0.1）lg PEIU /mL,significantly lower than in group A（1.8±0.2） lg PEIU/mL and（1.6±0.3） lg PEIU/L（P<0.05）;serum alanine aminotransferase,lactate dehydrogenase（LDH）,aspartate aminotransferase and adenosine deaminase（ADA） levels were significantly lower than in group A（P<0.05）;serum creatinine,cystatin C and urea nitrogen levels were significantly lower than in group A（P<0.05）;cytochrome P450 isoforms,e.g. CYP2E1,CYP2C9 and CYPIA2 were significantly lower than in group A（P<0.05）;serum creatine kinase and MDA levels were significantly lower than in group A （P<0.05）;serum glutathione （GSH） and superoxide dismutase （SOD） were significantly higher than in group A P<0.05）;serum HBV DNA loads in the two groups had no significant difference（P>0.05）. Conclusion Bailing capsule can reduce the risk of renal damage of entecavir in the treatment of patients with CHB.

Key words: Hepatitis B, Entecavir, Bailing capsule, Kidney damage